Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of JMT202 in Healthy Chinese Participants
NCT06564467Phase 1Enrolling by invitation
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertriglyceridemia, type 2 diabetes mellitus (T2DM) and obesity comparing JMT202 SAD Group with Placebo SAD Group (2 arms). Primary endpoints: Number of adverse events (AEs), Number of participants with clinically significant change from baseline in vital signs and 2 more. Started Jul 2024; status: enrolling by invitation.
02
Drugs
JMT202
03
Conditions
hypertriglyceridemiatype 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06564467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564467.